November 7, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Better MS Monitoring and Disease Understanding Among Goals of FLOODLIGHT Open, Genentech Director Says The ability to track multiple sclerosis (MS) at any time, gain a more complete picture of each patientās disease course and a better understanding of MS are among the possible benefits of the FLOODLIGHT app, according to Laura Julian, PhD, principal medical science director at Genentech. The company…
October 24, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Ocrevus Used Early in MS Course Key to Slowing Disability, Genentech Director Says Treating patients withĀ primary progressive or relapsing multiple sclerosis (MS) early with Ocrevus (ocrelizumab) is key to slowing disease progression, according to Hideki Garren, global head of Multiple Sclerosis and Neuroimmunology at Genentech. In an interview withĀ Multiple Sclerosis NewsĀ TodayĀ at the recentĀ 34thĀ congress of the European Committee for Treatment…
October 22, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Finding Best Treatment for ‘Right Patient’ and Progressive MS Among Work of Interest, Cleveland Clinic Doctors Say Tailored, highly effective therapies early in the disease’s course may be a way forward in multiple sclerosis (MS)Ā treatment, according to Cleveland Clinic neurologist Robert Bermel. Another neurologist with the Cleveland Clinic,Ā Robert Fox, talked about potential and upcoming progressive MS treatments.Ā In interviews with Multiple Sclerosis News…
October 18, 2018 News by Ana Pena PhD #ECTRIMS2018 ā High Vitamin D Levels, Smoking Predict Opposite Effects on Cognition in CIS Patients, Study Suggests High vitamin D levels predict better cognitive function, while smoking is associated with worse long-term cognitive disability in patients with clinically isolated syndrome (CIS), a study suggests. Data from the study was presented by MariannaĀ Cortese, MD, PhD, from the Department of Nutrition, Harvard T.H. Chan…
October 18, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – GNbAC1 Shows Consistent Neuroprotection in RRMS Patients, Phase 2b Study Reports TreatingĀ relapsing-remitting multiple sclerosis (RRMS) patients with GeNeuroās investigational compound GNbAC1 lessened brain atrophy and lesion load and suggested myelin preservation, according to results of a Phase 2b study. Importantly, monthly intravenous GNbAC1 administration for 48 weeks also had neuroprotective effects in the studyās inactive population, which refers…
October 18, 2018 News by Alice MelĆ£o, MSc #ECTRIMS2018 – Role of Brain Atrophy in MS Progression Poorly Understood by Patients, MSAA Survey Finds Although brain atrophy ā the loss of brain volume ā is an increasingly important measure in multiple sclerosis trials and treatment outcomes, MS patients have a limited understanding of its role in disease progression,Ā a survey reveals. This finding was detailed in the presentation ā…
October 17, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Serum Neurofilament Light Show Promise as Biomarker, But Not There Yet, Neurologists Say Despite its lack of specificity to multiple sclerosis (MS) in particular, monitoring patients with a blood biomarker ā serum neurofilament light (sNfL) ā may hold promise as a relatively easy way to assess treatment response and brain damage, according to MS experts. But there’s considerable work still to be…
October 17, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Blood Level of Neurofilament Light Chain May Predict Brain Atrophy in Progressive MS, Study Suggests Measuring the blood level of neurofilament light chain (NfL) may predict brain shrinkage in primary progressive (PPMS) and secondary progressive multiple sclerosis (SPMS), according to a new study. The findings also show that NfL levels are associated with brain lesion load in these patients. The research, ā…
October 17, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Stem Cell Transplant Effectively Lessens Disability in Patients with Aggressive MS, Study Finds Treatment with autologous hematopoietic stem cell transplant (aHSCT) led to a safe and rapid lessening of disability and no clinical relapses in patients with aggressive multiple sclerosis (MS), according to a new study. The research, āThe use of autologous hematopoietic stem cell transplantation as a…
October 17, 2018 News by Ana Pena PhD #ECTRIMS2018 – Evobrutinib Seen to Lower Active Brain Lesions in Phase 2 Trial Merck KGaA announced that evobrutinib, its oral candidate for relapsing multiple sclerosis (MS), was able to safely and significantly reduce active brain lesions overĀ 24 weeks of treatment, according to results of a Phase 2 study sponsored by the company.
October 16, 2018 News by Ana Pena PhD #ECTRIMS2018 – Shifting from Gilenya to Lemtrada Doesn’t Increase Risk of MS Reactivation, Study Says Shifting from treatment with Gilenya (fingolimod) to Lemtrada (alemtuzumab), and doing a short washout period between the two therapies, does not seem to increase the risk of disease reactivation in patients with multiple sclerosis (MS), an Italian study shows. Lemtrada, marketed by…
October 16, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Evobrutinib and Other Reasons for Hope in Pursuit of MS Treatments, Jerry Wolinsky Says in Interview Advances in multiple sclerosisĀ research and the development of new treatments over the last several decades give sustained reasons for hope as continue moving toward our future, according toĀ Jerry S. Wolinsky, a neurologist and MS specialist whose career spans more than 40 years. In a wide-ranging interview with Multiple…
October 16, 2018 News by BioNews Staff #ECTRIMS2018 – MS PATHS Just Starting to See Potential, Aims for Remission as Treatment Goal, Biogen Exec Says MS PATHS, a way of capturing data on disease progression and treatment response in thousands of multiple sclerosis (MS) patients being treated at any of 10 participating clinics, has among its goals that of making clinical remission ā a prolonged absence of any disease activity ā possible, said an…
October 16, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Two European Studies Compare Tecfidera, Aubagio Effectiveness Treatment of relapsing-remitting multiple sclerosis (RRMS) patients with Tecfidera (dimethyl fumarate)Ā is associated with fewer new brain lesions at two years, lower relapse rates, increased time to first relapse, and reduced treatment discontinuation than with Aubagio (teriflunomide), according to a nationwide study from France and a real-world, population-based…
October 16, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Study Examines Relapses When Stopping Gilenya During, After Pregnancy Up to half of women with multiple sclerosis (MS) who stop treatment with Gilenya (fingolimod) when planning to become pregnant will experience a relapse during pregnancy, according to a new study. The findings also revealed relapses over the first six months after giving birth in a quarter of…
October 15, 2018 News by Alice MelĆ£o, MSc #ECTRIMS2018 ā Additional Analysis on Ozanimod Demonstrates Its Potential to Treat Relapsing MS Additional analysis of clinical data from Celgeneās investigational agent ozanimod continues to demonstrate its potential to benefit patients with relapsing multiple sclerosis (MS). Findings from the Phase 3 SUNBEAM and RADIANCE Part B trials were discussed at the 34th Congress of the European Committee for Treatment and…
October 15, 2018 News by BioNews Staff #ECTRIMS2018 – Post-hoc Analyses Support Safety and Efficacy of Mavenclad, Merck KGaA Says Substantial data supporting both the effectiveness and safety of Mavenclad (cladribine tablets) is before the U.S. Food and Drug Administration (FDA), and may lead to its approval as a short-course oral treatment for people with relapsing-remitting multiple sclerosis (RRMS) some seven years after a first such request…
October 15, 2018 News by BioNews Staff #ECTRIMS2018 ā As Siponimod Awaits FDA Decision, Mouse Work Helps in Understanding Benefits Seen in SPMS Mouse studies ofĀ siponimod ā a potential progressive multiple sclerosis (MS) treatment that’s up for approval in the U.S. and EU ā were among presentations given by NovartisĀ at the 34th European Committee for Treatment and Research in Multiple SclerosisĀ (ECTRIMS), held Oct. 10-12 in Berlin. Animal work might seem…
October 15, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Plasma Neurofilament Light Levels Linked to Treatment Effects in RRMS, Study Finds Levels of proposed biomarker neurofilament light chain (NfL) are associated with therapeutic effects of disease-modifying treatments (DMTs) inĀ relapsing-remitting multiple sclerosisĀ (RRMS) patients, according to a real-world study. Study findings also revealed that treatment with either Lemtrada (alemtuzumab, marketed byĀ Sanofi Genzyme),Ā Gilenya (fingolimod, marketed by Novartis), Tecfidera (dimethyl fumarate, marketed…
October 15, 2018 News by Ana Pena PhD #ECTRIMS2018 – Smoking and Vitamin D Deficiency Likely to Worsen CIS Prognosis, Model Suggests Smoking and low levels of vitamin D can worsen prognosis for people with clinically isolated syndrome (CIS), researchers who developed a model for predicting long-term disability progression report. Their study, āPredicting the course of CIS patients adding…
October 15, 2018 News by Ana Pena PhD #ECTRIMS2018 – Excessive Weight, But Not Vitamin D, Linked with Faster Grey Matter Loss in MS, Study Finds Being overweight is associated with accelerated grey matter volume loss in the brain, a mark ofĀ neurodegeneration, in multiple sclerosis (MS) patients, a five-year observational study shows. But vitamin D levels, often suggested as an MS risk factor, do not seem to affect brain volume over time.
October 12, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018: Study Proposes Serum Neurofilament Light Threshold to Identify RRMS Patients at Risk of Worsening Relapsing-remitting multiple sclerosis (RRMS) patients with serum neurofilament light chain (sNfL) levels higher than a proposed threshold have a higher risk of disease activity, and worsened disability, lesions and brain shrinkage in the long term, according to a new study. The research, āSerum neurofilament light (NfL)…
October 12, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 ā In CIS Patients, Early Lesions in Specific Brain Area Linked to Worse Disability 30 Years Later, Study Shows Lesions in the infratentorial region of the brain at the onset ofĀ clinically isolated syndrome (CIS) and lesions in white matter one year after CIS onset are associated with worse disability 30 years later, a study reports. The study, āEarly MRI predictors of long-term multiple sclerosis outcomes:…
October 12, 2018 News by BioNews Staff #ECTRIMS2018 – From Sun to Salt: Growing Role of Environment in MS A person’s genes influence the development of multiple sclerosis (MS), but so does the environment ā both that in which an MS patient lives, and that which a patient creates through diet and other lifestyle choices, researchers said in a Thursday session at the 34th congress of the European…
October 12, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 ā Early Relapses and Larger Lesions Increase Risk of Developing SPMS, Study Reports A higher frequency of early relapses, as well as a larger volume of lesions and older age at disease onset, increase the risk of transitioning from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS), according to a study. The study, āEarly cortical pathology and…
October 12, 2018 News by Alice MelĆ£o, MSc #ECTRIMS2018 – MS Patients More Prone to Health Problems Before, After Diagnosis, Study Suggests Patients with multiple sclerosis (MS) are more likely to experience health problems before they receive their formal diagnosis, as well as to experience serious non-MS-related complications after diagnosis, a study reveals. The findings were reported in the study āIncreased risk of…
October 11, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 ā Infections, Severe Disability Complications More Likely Causes of Death in MS Patients, Study Shows Infections and complications from severe disability are the greatest contributors to mortality amongĀ multiple sclerosis (MS) patients, according to a population-based study in British Columbia, Canada, which also found that that MS is a more common underlying cause of death among younger patients. The study, āCauses that…
October 11, 2018 News by Ana Pena PhD #ECTRIMS2018 ā MS Patients with Depression or Bipolar Disorder at Higher Risk of Disability Worsening, Study Finds Multiple sclerosis (MS) patients with depression or bipolar disorder may be at higher risk of becoming incapacitated and seeing their disability worsen faster, according to a Swedish study. A depressive state may increase the central nervous system response’s to inflammation and accelerate the…
October 11, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Brain, Spinal Cord Injuries Affect Processing Speed in MS Patients, Study Reveals Processing speed is associated with the extent of brain and spinal cord injury in patients with multiple sclerosis (MS), according to a new study conducted in a clinical setting. The results support using the Processing Speed Test (PST) in both clinical practice and trials. The study, ā…
October 11, 2018 News by BioNews Staff #ECTRIMS2018 ā Data from 2 EU Trials Shows Effectiveness of Cannabidiol Spray in Treating Spasticity Data from two European trials ā a real-life study in Italy, and a long-term Czech trial looking at impact on cognition ā supported the efficacy of a widely approved cannabinoid spray in treating moderate to severe spasticity (muscular stiffness or involuntary spasms) in multiple sclerosis (MS) patients who…